KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva, Switzerland & More News Here

---

Get prompt alerts when information breaks in your shares. Claim your 1-week free trial to StreetInsider Premium right here.

---

GENEVA–(BUSINESS WIRE)–
KBI Biopharma SA (KBI) and Selexis SA, each JSR Life Sciences corporations, introduced right now that an expanded, fully-integrated mammalian contract improvement and manufacturing providers facility is now open and operational in Geneva, Switzerland.

This press launch options multimedia. View the total launch right here: https://www.businesswire.com/news/home/20220613005062/en/

The ~94,000 square-foot built-in KBI/Selexis state-of-the-art facility builds upon the businesses’ present market foothold by combining best-in-class cell line improvement (CLD) and skilled mammalian cell manufacturing in a single location. KBI and Selexis leverage their experience and environment friendly end-to-end providers for biomanufacturing shoppers.

This enlargement allows industry-leading supply of shopper applications by elevated high quality, effectivity, and time financial savings throughout a various portfolio of molecule codecs. Under one roof, KBI and Selexis present cell line transfection by cGMP drug manufacturing with Selexis’ specialised high-titer mammalian cell line improvement applied sciences and providers and KBI’s cGMP bulk drug manufacturing for scientific and industrial necessities.

“This expansion in Geneva will provide our global clients with streamlined capabilities to support mammalian-based therapies,” stated Mark W. Womack, Chief Executive Officer for KBI Biopharma and Selexis SA. “With a single touchpoint for best-in-class cell line development, process development, and manufacturing, clients experience heightened access to our process and product-based expertise.”

He added, “This facility expansion, together with our track record in the space, strengthens our commitment to deliver a seamless experience to the European biopharmaceutical community and clients around the globe.”

The totally built-in Selexis and KBI improvement platform has supported greater than 60 scientific improvement applications with excessive productiveness and sturdy product high quality. The two corporations have developed a seamless method, to optimize the shopper expertise.

“We have always been a science-driven, customer-centric company. This expansion in Geneva helps our clients optimize their complex biomanufacturing processes under accelerated timelines,” stated Ulrich Valley, Senior Vice President, Operations & Site Head, KBI Biopharma, Geneva.

The KBI Biopharma facility will create greater than 200 technical positions in improvement, operations, and high quality assurance. The facility features a suite of analytical testing laboratories and twin 2,000L single-use cGMP manufacturing trains with downstream processes able to producing 8-10 kg yields per batch.

With the expanded Geneva facility now operational, KBI and Selexis will rejoice with ribbon-cutting actions and facility excursions beginning in July 2022.

About KBI Biopharma, Inc.

KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences firm. KBI Biopharma is a number one world contract improvement and manufacturing group (CDMO) offering totally built-in, accelerated drug improvement and biologics manufacturing providers and experience to life science corporations. With every of its 500+ shopper companions, KBI works intently to personalize and speed up drug improvement applications. Built upon a basis of world-class analytics capabilities and in depth scientific and technical experience, KBI delivers sturdy course of improvement and scientific and industrial cGMP manufacturing providers for mammalian, microbial, and cell remedy applications. Recognized for high quality manufacturing, KBI helps shoppers advance drug candidates into the clinic and past. KBI serves its world shoppers with a number of places in Europe and the USA. www.kbibiopharma.com.

About Selexis SA.

Selexis SA, a JSR Life Sciences firm, is the worldwide chief in cell line improvement with best-in-class modular expertise and extremely specialised options that allow the life sciences {industry} to quickly uncover, develop, and commercialize revolutionary medicines and vaccines. Our world companions have utilized Selexis applied sciences to advance greater than 158 drug candidates in preclinical and scientific improvement and manufacture ten industrial merchandise. As a part of a complete drug improvement course of, the Company’s applied sciences shorten improvement timelines and cut back manufacturing dangers. More data is obtainable at www.selexis.com.

View supply model on businesswire.com: https://www.businesswire.com/news/home/20220613005062/en/

KBI Biopharma Company Inquiries

Aruna Mor

KBI Biopharma, Inc.

[email protected]

KBI Biopharma, Inc. Media Contact

Blair Ciecko

CG Life

[email protected]

Source: KBI Biopharma SA

I’ve tried to provide every kind of stories to all of you latest news today 2022 by this web site and you’re going to like all this information very a lot as a result of all of the information we at all times give in this information is at all times there. It is on trending subject and regardless of the newest information was

it was at all times our effort to achieve you that you simply maintain getting the newest information and you at all times maintain getting the data of stories by us without cost and additionally inform you folks. Give that no matter data associated to different kinds of information might be

made obtainable to all of you so that you’re at all times linked with the information, keep forward in the matter and maintain getting today news all kinds of information without cost until right now so as to get the information by getting it. Always take two steps ahead